SMTI vs. BLFS, ESTA, MDXG, INMD, BBNX, SIBN, IRMD, RXST, CBLL, and EMBC
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include BioLife Solutions (BLFS), Establishment Labs (ESTA), MiMedx Group (MDXG), InMode (INMD), Beta Bionics (BBNX), SI-BONE (SIBN), Iradimed (IRMD), RxSight (RXST), CeriBell (CBLL), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.
Sanara MedTech vs. Its Competitors
BioLife Solutions (NASDAQ:BLFS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 54.1% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Sanara MedTech had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 6 mentions for Sanara MedTech and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.35 beat Sanara MedTech's score of 1.03 indicating that BioLife Solutions is being referred to more favorably in the media.
Sanara MedTech has a net margin of -10.71% compared to BioLife Solutions' net margin of -38.98%. BioLife Solutions' return on equity of -6.61% beat Sanara MedTech's return on equity.
Sanara MedTech has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.
BioLife Solutions has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.
BioLife Solutions received 289 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 66.74% of users gave BioLife Solutions an outperform vote while only 61.54% of users gave Sanara MedTech an outperform vote.
BioLife Solutions currently has a consensus price target of $31.17, indicating a potential upside of 31.62%. Sanara MedTech has a consensus price target of $49.50, indicating a potential upside of 70.45%. Given Sanara MedTech's higher probable upside, analysts clearly believe Sanara MedTech is more favorable than BioLife Solutions.
Summary
BioLife Solutions beats Sanara MedTech on 11 of the 17 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
This page (NASDAQ:SMTI) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy SMTI Stock Free SMTI Stock Alerts